Quince Therapeutics to Acquire EryDel SpA and P-III Lead Asset EryDex Targeting Ataxia-Telangiectasia
Shots:
- EryDel stockholders will receive ~$485M in total downstream cash fees incl. ~ $5M in development milestones, $25M at NDA acceptance, $60M in approval milestones & $395M in market & sales milestones with no royalties. The transaction is expected to close in Q3’23 & will incl. the assumption of EryDel’s $13M EIB loan with scheduled payments beginning in H2’26
- The acquisition will advance EryDel’s AIDE technology & development of EryDex to deliver innovative treatments to patients. EryDel stockholders will own 16.7% of the combined company & will operate as a wholly owned subsidiary of Quince with plans to retain EryDel’s corporate & manufacturing presence in Italy
- EryDex received ODD from the US FDA & EMA for Ataxia-Telangiectasia (A-T) & has completed a pilot P-II trial in A-T patients. The first patient is expected to enroll in the P-III trial for EryDex in Q2’24 with NDA submission at the end of 2025
Ref: Businesswire | Image: Quince Therapeutics
Related News:- Acasti Reports Results of GTX-102 in P-I Bridging Study for the Treatment of Ataxia Telangiectasia
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
